vs
Side-by-side financial comparison of Metallus Inc. (MTUS) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Metallus Inc. is the larger business by last-quarter revenue ($308.3M vs $177.4M, roughly 1.7× Pacira BioSciences, Inc.). Metallus Inc. runs the higher net margin — 1.8% vs 1.6%, a 0.1% gap on every dollar of revenue. On growth, Metallus Inc. posted the faster year-over-year revenue change (9.9% vs 5.0%). Over the past eight quarters, Metallus Inc.'s revenue compounded faster (2.3% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
MTUS vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $308.3M | $177.4M |
| Net Profit | $5.4M | $2.9M |
| Gross Margin | 8.1% | — |
| Operating Margin | — | 3.9% |
| Net Margin | 1.8% | 1.6% |
| Revenue YoY | 9.9% | 5.0% |
| Net Profit YoY | 315.4% | — |
| EPS (diluted) | $0.13 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $308.3M | $177.4M | ||
| Q4 25 | $267.3M | $196.9M | ||
| Q3 25 | $305.9M | $179.5M | ||
| Q2 25 | $304.6M | $181.1M | ||
| Q1 25 | $280.5M | $168.9M | ||
| Q4 24 | $240.5M | $187.3M | ||
| Q3 24 | $227.2M | $168.6M | ||
| Q2 24 | $294.7M | $178.0M |
| Q1 26 | $5.4M | $2.9M | ||
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $8.1M | $5.4M | ||
| Q2 25 | $3.7M | $-4.8M | ||
| Q1 25 | $1.3M | $4.8M | ||
| Q4 24 | $-21.4M | — | ||
| Q3 24 | $-5.9M | $-143.5M | ||
| Q2 24 | $4.6M | $18.9M |
| Q1 26 | 8.1% | — | ||
| Q4 25 | 2.2% | 79.5% | ||
| Q3 25 | 11.4% | 80.9% | ||
| Q2 25 | 10.6% | 77.4% | ||
| Q1 25 | 7.8% | 79.7% | ||
| Q4 24 | 4.5% | 78.7% | ||
| Q3 24 | 5.3% | 76.9% | ||
| Q2 24 | 8.2% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -7.7% | 1.2% | ||
| Q3 25 | 3.6% | 3.5% | ||
| Q2 25 | 2.8% | 4.7% | ||
| Q1 25 | 1.0% | 1.2% | ||
| Q4 24 | -10.1% | 13.2% | ||
| Q3 24 | -3.1% | -82.8% | ||
| Q2 24 | 2.1% | 15.9% |
| Q1 26 | 1.8% | 1.6% | ||
| Q4 25 | -5.3% | — | ||
| Q3 25 | 2.6% | 3.0% | ||
| Q2 25 | 1.2% | -2.7% | ||
| Q1 25 | 0.5% | 2.8% | ||
| Q4 24 | -8.9% | — | ||
| Q3 24 | -2.6% | -85.1% | ||
| Q2 24 | 1.6% | 10.6% |
| Q1 26 | $0.13 | $0.07 | ||
| Q4 25 | $-0.34 | $0.05 | ||
| Q3 25 | $0.19 | $0.12 | ||
| Q2 25 | $0.09 | $-0.11 | ||
| Q1 25 | $0.03 | $0.10 | ||
| Q4 24 | $-0.46 | $0.38 | ||
| Q3 24 | $-0.13 | $-3.11 | ||
| Q2 24 | $0.10 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $104.0M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $683.0M | $653.9M |
| Total Assets | $1.1B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $104.0M | $144.3M | ||
| Q4 25 | $156.7M | $238.4M | ||
| Q3 25 | $191.5M | $246.3M | ||
| Q2 25 | $190.8M | $445.9M | ||
| Q1 25 | $180.3M | $493.6M | ||
| Q4 24 | $240.7M | $484.6M | ||
| Q3 24 | $254.6M | $453.8M | ||
| Q2 24 | $272.8M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | $0 | $376.7M | ||
| Q2 25 | $0 | $580.5M | ||
| Q1 25 | $5.4M | $583.4M | ||
| Q4 24 | $5.4M | $585.3M | ||
| Q3 24 | $13.2M | — | ||
| Q2 24 | $13.2M | — |
| Q1 26 | $683.0M | $653.9M | ||
| Q4 25 | $686.0M | $693.1M | ||
| Q3 25 | $697.7M | $727.2M | ||
| Q2 25 | $690.0M | $757.8M | ||
| Q1 25 | $686.1M | $798.5M | ||
| Q4 24 | $690.5M | $778.3M | ||
| Q3 24 | $712.7M | $749.6M | ||
| Q2 24 | $736.3M | $879.3M |
| Q1 26 | $1.1B | $1.2B | ||
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.2B | $1.3B | ||
| Q2 25 | $1.1B | $1.5B | ||
| Q1 25 | $1.1B | $1.6B | ||
| Q4 24 | $1.1B | $1.6B | ||
| Q3 24 | $1.1B | $1.5B | ||
| Q2 24 | $1.1B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | 0.00× | 0.52× | ||
| Q2 25 | 0.00× | 0.77× | ||
| Q1 25 | 0.01× | 0.73× | ||
| Q4 24 | 0.01× | 0.75× | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.02× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MTUS
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
